MOUNTAIN VIEW, Calif., March 5 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, announced today that Dan Weiner, Ph.D., Senior Vice President, Software, will speak to members of the pharmaceutical and biotechnology industries at two workshops on March 7, 2007 in East Brunswick, New Jersey and on March 13 in Burlingame, California. Both half-day workshops begin at 9:00 AM local time and are free to Pharsight customers and invited guests.
Dr. Weiner will discuss FDA’s view on the role of modeling and simulation in drug development and approval and will describe how biopharmaceutical companies and FDA are leveraging their investment in WinNonlin to produce productive, regulatory-compliant pharmacokinetic (PK) workflows. The workshops will include presentations from Dr. Weiner, Pharsight staff, and invited industry experts on solutions for PK data management and for automated PK analysis and reporting. The workshop agenda will also include perspectives on challenges and opportunities for sharing unified data and models across the development organization, interdisciplinary attendee discussion, and product demonstrations. Additional information is available at http://www.pharsight.com.
“These workshops provide an important opportunity to discuss how deploying software technology, notably state-of-the-art PK/PD data management, analysis and reporting systems, is a key enabler of a more rational and cost-effective drug development process,” said Shawn O’Connor, president and CEO of Pharsight. “Pharsight is pleased to host these gatherings of our customers, industry practitioners and other invited guests to exchange information and discuss the technical infrastructure required to support the strategic application of modeling and simulation as outlined in FDA’s Critical Path Initiative.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight(R) and WinNonlin(R) are registered trademarks of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders
Pharsight Corporation
CONTACT: Investors, Douglas Sherk or Jennifer Beugelmans, +1-415-896-6820;or Media, Jennifer Saunders, +1-646-201-5431, all of EVC Group forPharsight Corporation
Web site: http://www.pharsight.com/
